Skip to main content
. 2017 Dec 15;9(10):8985–8998. doi: 10.18632/oncotarget.23739

Figure 4. JARID1B-mediated E-cadherin repression in OSCC can be demethylase-independent.

Figure 4

(A) E-cadherin (CDH1) mRNA by QRT-PCR after transient siRNA knockdown of JARID1B (left) or 5-day treatment with CPI-455 (20 μM, right). *p < 0.025, **p < 0.01 (B) E-cadherin (CDH1) mRNA by QRT-PCR after transiently overexpressing WT or mutant (H499Y) JARID1B. *p < 0.025, **p < 0.01, ***p < 0.005 (C) ZEB1 mRNA expression in OCTT2 cells by QRT-PCR after transient siRNA knockdown of JARID1B (left) or 5-day treatment with CPI-455 (20 μM, right). *p < 0.05 (D) ZEB1 mRNA in OCTT2 cells by QRT-PCR after transiently overexpressing WT or mutant (H499Y) JARID1B. *p < 0.025, **p < 0.0001 (E) Transwell collagen invasion relative to indicated controls after transiently overexpressing WT or mutant (H499Y) JARID1B. *p < 0.05, **p < 0.0025 (F) Transwell collagen invasion after transient siRNA knockdown of JARID1B (left) or 5-day treatment with CPI-455 (20 μM, right). *p < 0.025, **p < 0.01 (G) OCT4 and SOX2 mRNA expression by QRT-PCR after transiently overexpressing WT or mutant (H499Y) JARID1B. *p < 0.05, **p < 0.025, ***p < 0.01 (H) Model proposing segregation of demethylase-dependent vs independent actions of JARID1B that dictate the response to catalytic inhibition.